Home page >> Mark Freedman

Mark Freedman

Dr. Freedman is currently professor of medicine in the field of neurology at the University of Ottawa, as well as director of the Multiple Sclerosis Research Unit at the Ottawa Hospital, General Campus and a Senior Scientist at the Ottawa Hospital Research Institute.  A graduate of the University of Toronto, Dr. Freedman holds his Masters Degree in Molecular Neurochemistry and continued his postgraduate work specializing in neurology and neuroimmunology.   His specialized training took him to the Weizmann Institute of Science, Israel; The National Hospital, Queen Square, London UK, as well as the Montreal Neurological Institute, where he subsequently was an Assistant Professor. He then joined the University of Ottawa where he rose through the ranks to a Full Professor in 1998. He holds his specialist certification in Quebec CSPQ and all of Canada FRCP(C) and is a Fellow of both the American Neurological Association (FANA) and the American Academy of Neurology (FAAN).

Dr. Freedman has published over 350 pieces articles, 450 abstracts as well as numerous books and book chapters and has been invited to give hundreds of lectures and presentations nationally and internationally.  His extensive research includes the area of molecular neurochemistry, cellular immunology, neuroimmunology and clinical studies in MS.  He is currently holding peer reviewed and industry related funding for translational research investigating immune mechanisms of damage and repair in multiple sclerosis, with a particular interest in cell-based therapies.  He was the lead investigator in the Canadian Bone Marrow Transplant Study in MS, is currently the head of the Canadian Mesenchymal Stem Cell Transplantation in MS study (MESCAMS) and co-director of the International Mesenchymal Stem Cell Transplantation in MS Study Group.

Dr. Freedman has over 35 years of experience in the management of patients with multiple sclerosis and has been the principal investigator on numerous clinical trials with new therapeutic agents for MS.  He has experience from serving on several research study steering committees as well as data safety monitoring boards.  He serves on the editorial boards for several journals including the Multiple Sclerosis Journal. He has also served on several national and international committees and is currently the President-Elect of the Americas Committee for Treatment and Research in MS (ACTRIMS).

CONy Section Heads

Add Your Heading Text Here